Literature DB >> 475369

In vitro of cefotaxime against cephalothin-resistant clinical isolates.

H W Van Landuyt, M Pyckavet.   

Abstract

Cefotaxime is more active than six other cephalosporins against 150 cephalothin-resistant Enterobacteriaceae strains and is the only drug which is more active than ampicillin against Haemophilus. It shows a potentially useful activity against Pseudomonas.

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 475369      PMCID： PMC352800          DOI： 10.1128/AAC.16.1.109

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  12 in total

1.  beta-lactamase stability of HR 756, a novel cephalosporin, compared to that of cefuroxime and cefoxitin.

Authors:  K P Fu; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1978-09       Impact factor: 5.191

2.  Activity of HR 756 against Haemophilus influenzae, Bacteroides fragilis and Gram-negative rods.

Authors:  F A Drasar; W Farrell; A J Howard; C Hince; T Leung; J D Williams
Journal:  J Antimicrob Chemother       Date:  1978-09       Impact factor: 5.790

3.  Cefotoxime (HR 756) a new cephalosporin with exceptional broad-spectrum activity in vitro.

Authors:  J M Hamilton-Miller; W Brumfitt; A V Reynolds
Journal:  J Antimicrob Chemother       Date:  1978-09       Impact factor: 5.790

4.  Haemophilus influenzae type B resistant to ampicillin. A report of two cases.

Authors:  W Khan; S Ross; W Rodriguez; G Controni; A K Saz
Journal:  JAMA       Date:  1974-07-15       Impact factor: 56.272

5.  Experimental evaluation of HR756, a new cephalosporin derivative: pre-clinical study.

Authors:  R Heymès; A Lutz; E Schrinner
Journal:  Infection       Date:  1977       Impact factor: 3.553

6.  Antibiotic susceptibility of gram-negative bacilli isolated from blood cultures. Results of tests with 35 agents and strains from 169 patients at Boston City Hospital during 1972.

Authors:  J E McGowan; C Garner; C Wilcox; M Finland
Journal:  Am J Med       Date:  1974-08       Impact factor: 4.965

7.  Cefuroxime, a new cephalosporin antibiotic: activity in vitro.

Authors:  C H O'Callaghan; R B Sykes; A Griffiths; J E Thornton
Journal:  Antimicrob Agents Chemother       Date:  1976-03       Impact factor: 5.191

8.  Comparison of the antibacterial activity of nine cephalosporins against Enterobacteriaceae and nonfermentative gram-negative bacilli.

Authors:  L Verbist
Journal:  Antimicrob Agents Chemother       Date:  1976-10       Impact factor: 5.191

9.  Cefoxitin, a semisynthetic cephamycin antibiotic: susceptibility studies.

Authors:  H Wallick; D Hendlin
Journal:  Antimicrob Agents Chemother       Date:  1974-01       Impact factor: 5.191

10.  Antibacterial activity of cefamandole, a new cephalosporin antibiotic, compared with that of cephaloridine, cephalothin, and cephalexin.

Authors:  S Eykyn; C Jenkins; A King; I Phillips
Journal:  Antimicrob Agents Chemother       Date:  1973-06       Impact factor: 5.191
View more
  10 in total

1.  Comparative in vitro activities of amoxicillin-clavulanic acid, cefuroxime, cephalexin, and cephalothin against trimethoprim-resistant Escherichia coli isolated from stools of children attending day-care centers.

Authors:  K V Singh; R R Reves; L K Pickering; B E Murray
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

2.  In vitro activities of cefotaxime and moxalactam (LY127935) against Haemophilus influenzae.

Authors:  J H Jorgensen; S A Crawford; G A Alexander
Journal:  Antimicrob Agents Chemother       Date:  1980-03       Impact factor: 5.191

3.  In vitro antimicrobial activity of cefotaxime, a new cephalosporin.

Authors:  S Masuyoshi; S Arai; M Miyamoto; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1980-07       Impact factor: 5.191

4.  Comparison of cefoperazone, cefotaxime, and moxalactam (LY127935) against aerobic gram-negative bacilli.

Authors:  S D Lang; D J Edwards; D T Durack
Journal:  Antimicrob Agents Chemother       Date:  1980-03       Impact factor: 5.191

5.  Cefotaxime: in vitro activity and tentative interpretive standards for disk susceptibility testing.

Authors:  P C Fuchs; A L Barry; C Thornsberry; R N Jones; T L Gavan; E H Gerlach; H M Sommers
Journal:  Antimicrob Agents Chemother       Date:  1980-07       Impact factor: 5.191

6.  Clinical efficacy of cefotaxime in serious infections.

Authors:  P H Karakusis; J M Feczko; L J Goodman; D M Hanlon; A A Harris; S Levin; G M Trenholme
Journal:  Antimicrob Agents Chemother       Date:  1982-01       Impact factor: 5.191

7.  Serum bactericidal activity of moxalactam and cefotaxime with and without tobramycin against Pseudomonas aeruginosa and Staphylococcus aureus.

Authors:  H Lagast; S H Zinner; J Klastersky
Journal:  Antimicrob Agents Chemother       Date:  1981-10       Impact factor: 5.191

8.  Cefmenoxime (SCE-1365), a new cephalosporin: in vitro activity, comparison with other antimicrobial agents, beta-lactamase stability, and disk diffusion testing with tentative interpretive criteria.

Authors:  P C Fuchs; R N Jones; C Thornsberry; A L Barry; E H Gerlach; H M Sommers
Journal:  Antimicrob Agents Chemother       Date:  1981-12       Impact factor: 5.191

9.  Penetration of cefotaxime into the aqueous humour of the human eye after intravenous application.

Authors:  C D Quentin; R Ansorg
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1983       Impact factor: 3.117

Review 10.  The cephalosporins: activity and clinical use.

Authors:  A J Weinstein
Journal:  Drugs       Date:  1980-08       Impact factor: 9.546
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.